WINNIPEG, MANITOBA--(Marketwire - December 04, 2007) - Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that it has reached an agreement with Diagnos Inc.(TSX VENTURE: ADK), a leader in the use of artificial intelligence (AI) and advanced knowledge extraction techniques, to provide services towards the development of Miraculins’ cancer diagnostic discovery programs.
